Back to Trades
Total Value
$399.7M
Net $399.7M sold
Filing Date
Jun 23, 2026
1 transaction
Sales
$399.7M
1 transaction
Trade Summary
On Jun 23, 2026, Fairmount Funds Management LLC, Director, sold $399.7M of Spyre Therapeutics, Inc. (SYRE) across 1 transaction. The filing covers Common Stock and reflects net selling of $399.7M. Reported prices ranged from $85.31. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Spyre Therapeutics, Inc.
- Ticker Symbol
- SYRE
- CIK
- 0001636282
Insider Information
- Role
- Director
- Location
- WEST CONSHOHOCKEN, PA
Filing Details
- Filing Date
- Jun 23, 2026
- Transaction Date
- Jun 23, 2026
- Accession Number
- 0001104659-26-076967
- Form Type
- 4
- Net Trading Amount
- -$399.7M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jun 23, 2026 | Common Stock | 666,680 | — | C | — |
| Jun 23, 2026 | Common Stock | 4,684,781 | $85.31 | Sale | $399.7M |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jun 23, 2026 | SYRE derivative | 16,667 | — | C | — |
Want live alerts when Fairmount Funds Management LLC trades again?
Download Insider Trades to track SYRE, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)Each share of Series B Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On June 23, 2026, the Reporting Persons converted 16,667 shares of Series B Preferred Stock into 666,680 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designations for the Series B Convertible Preferred Stock.
- (F2)Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- (F3)Each share of Series A Preferred Stock is convertible at the option of the holder into 40 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series A Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.